Amy Ryan represents philanthropists, private foundations, public charities, medical research organizations, and other tax-exempt organizations in a broad range of transactions. Ms. Ryan has experience with developing novel funding policies to achieve an exempt organization's intellectual property goals; establishing collaborations between a medical research organization and its partner hospital(s); crafting multi-party consortium arrangements with cooperative intellectual property and data sharing aspects; and counseling exempt organizations on program related and mission related investments. Ms. Ryan has been instrumental in structuring several of the largest venture philanthropy transactions in recent years.
Ms. Ryan also has a deep background in assisting commercial companies in the life sciences sector with drafting and negotiating a broad range of contracts for the commercialization and protection of intellectual property and technology. Her experience in this capacity includes drafting and negotiating license agreements, development agreements, collaboration agreements, clinical study agreements, technology transfer agreements, and manufacturing and distribution agreements.
- The Gilbert Family Foundation in its $12 million gene therapy initiative which will fund multiple multi-disciplinary research teams to identify which gene therapy techniques are most promising for patients living with neurofibromatosis type 1.
- Philanthropic Foundation in a $17.5 million grant to a biotechnology company in support of a viral diagnostic development program.
- Medical Research Organization in a multi-hundred million dollar collaboration with three (3) medical research institutions aiming to cure, manage, and prevent diseases.
- The Mark Foundation for Cancer Research (U.S.) Ltd. in a major grant transaction with Cambridge University to establish The Mark Foundation Institute for Integrated Cancer Medicine at Cambridge, a new institute that aims to revolutionize cancer care by maximizing big data collected from patients. The virtual institute aims to exploit recent advances in big data processing and machine learning to capture and integrate clinical, genomic, and image data collated from hundreds of cancer patients in real time.
- The Parker Institute for Cancer Immunotherapy in its establishment of a $250 million cancer immunotherapy research consortium comprised of six academic and medical research institutions, including a novel, collaborative approach to centralized tech transfer and commercialization processes across participating institutions.
- The Sean N. Parker Foundation in its $24 million gift to Stanford University for the establishment of the Sean N. Parker Center for Allergy and Asthma Research at Stanford.
- The Lieber Institute for Brain Development in its formation and affiliation with Johns Hopkins University; developed intellectual property, publications, and conflicts policies for the institute; advised on material transfers, licenses, and collaborations with other researchers and private companies.
- The Juvenile Diabetes Research Foundation in its development and implementation of an intellectual property policy with nine (9) university and academic medical center grant recipients involved in the Artificial Pancreas Project.
- In a transaction recognized by the Licensing Executives Society as a Deal of Distinction™, a leading global pharmaceutical company in a pioneering drug discovery and development collaboration with a major US university. The deal was cited as being an innovative and "excellent illustration of the interface between industry and academia."
- Leading US biopharmaceutical company in its negotiations with a major medical center to develop a strategic alliance that will design and conduct clinical trials for oncology product candidates.
- JD, Georgetown University Law Center, 1999, cum laude
- BA, University of Virginia, 1988
- District of Columbia